INTRODUCTION
MRI is increasingly used for assessment of small bowel diseases. MRI has a high diagnostic accuracy and reproducibility, both with enteroclysis and the oral contrast method (enterography) for evaluation of inflammatory diseases and malabsoption syndrome (celiac disease).
The dilemma between the oral approach in MR enterography (MREg), which is more acceptable to patients and the intubation-infusion method in MR enteroclysis (MREc), which is less tolerated, in the absence of conscious sedation, has not been resolved by the radiologic community [1] [2] [3] . Patient's more acceptable MREg has potentional intrinsic advantages over both computed enteroclysis (CTE) and capsule enteroscopy (CE) due to the avoidance of ionizing radiation exposure, safety in pregnancy, detecting extraluminal, intraluminal and perianal disease 4 . MREg gives excellent soft tissue resolution and allows comparison of initial evaluation and lifelong follow-up. The proper examination of small and large bowel requires intraluminal contrast agents for lumen opacity,luminal distension and high contrast resolution between the lumen and the bowel wall. Adequate bowel distension for MREg is achieved by non osmotic agents without the intubation technique and water resorption is slowed down. Contrast agents need to meet the following requirements: minimal mucosal absorption, absence of artifacts, no significant adverse effects and low cost 5 . There are 3 main groups of intraluminal contrast agents based on providing signal intensity depending on the used pulse sequence. Positive contrast agents (high signal on T2 and T1-weighted images) are gadolinium chelates, manganese chloride, ferrous ammonium citrates, etc. The second group includes biphasic contrast agents (low signal on T1 and high signal on T2-weighted images) like polyethylenglycol (PEG), mannitol/sorbitol, water, methylcellulose (Vidogum), (locust bean gum) (ref. 5 ), (VoLumen) (ref.
6 ) ( Fig. 1,2 ). Negative contrast agents (low signal on T2/T2* and T1-weighted images) are solutions with Super Paramagnetic Iron Oxides (SPIO) nanoparticles for MRI diagnostics, e.g. AMI-121 (ferumoxsil Lumirem and Gastromark, Malinckrodt) (Fig. 3,4) , OMP (Abdoscan, Nycomed,Amershem), perfluorooctylbromide (Imagent GI), perfluorocarbon [7] [8] [9] . Ultrasmall Superparamagnetic Iron Oxides (USPIO) for liver/spleen MR imaging are experimentally used, e.g. AMI-25 (Endorem and Feridex IV), SHU 555A (Resovist). Smaller iron oxide particles are selected for lymph node imaging (AMI-227 -Sinerem and Combidex), bone marrow imaging (AMI-227), perfusion imaging (NC100150 -Clariscan) and MR angiography (NC100150) (ref. 10 ). SPIO nanoparticles are strong proton enhancers resulting in shortening both T1 and T2 relaxation times and thus by dephasing spins (susceptibility effect) superparamagnetic particles cause decrease in the signal intensity on T2 weighted images 9 . Negative contrast agents decrease noise and motion artifacts related to the bowel peristalsis and improve the detection of intramural edema and extramural complications (necrosis, fat edema, mesenterial edema, abscess formation or fistulas) (ref. 11, 12 ). SPIO negative contrast agents are appropriate for MRCP as they decrease the non-homogenous signal of the bowel lumen and the desired organ such as biliary duct or pancreas can be better visualized. Currently commercial oral bowel negative contrast agents are still not used routinely due to the high investigational costs. Kluchova, et al. described and provided a new negative contrast agent composed of superparamagnetic nearly monodispersed maghemite nanoparticles prepared by thermal induced solid-state reaction from iron (II) acetate in air that are incorporated in a layered aluminosilicate mineral (bentonite matrix). Bentonite is a natural, lowcost, readily available and biocompatible aluminosilicate mineral endowed with unique swelling, sorpsion, ionexchange and intercalation properties. The clay is known to be essentially nontoxic and established by the Food and Drug Administration as "Generally Recognized As Safe" (GRAS). The detailed process of synthesis, physical and chemical characterization of this new oral negative SPIO contrast agent is reported by Kluchova et al. 8 . The aim of this study was to test the experimental SPIO oral solution -maghemite in MRI of healthy volunteers,patients with chronic inflammatory small bowel diseases, and MRCP.
PATIENTS AND METHODS

Patients
The study was conducted in cooperation of the Department of Radiology, F.D.Roosevelt Faculty Hospital Banska Bystrica (Slovak Republic) with the Regional Center of Advanced Material, Palacky University, Olomouc (Czech Republic) between March 2008 and October 2009. All participating volunteers and patients signed informed consent approved by ethics committee.
The experimental oral negative contrast solution was tested in 3 cohorts: 17 healthy volunteers (group A) underwent MREg, 24 patients with small bowel disease underwent MRCP (group B) and 22 patients with small bowel disease (group C) underwent MREg. Volunteers and patients fasted 6-8h before examination. Characteristics of the study samples are summarized in (Table 1) . There was no significant differences in gender between groups 
002).
All patients and volunteers completed questionnaires evaluating the solution characteristics (amount, taste, characteristic of taste, appearance). A four-step scoring system was used to evaluate the amount of experimental solution (1.sufficient, 2.excessive, 3.insufficient, 4.unknown) evaluated by patients and volunteers, taste (1.perfect, 2.good, 3.bad, 4.another-specify), characteristic of taste (1.fruity, 2.metallic, 3.synthetic, 4.another-specify) and appearance (1.perfect, 2.good-looking, 3.bad-looking, 4.another-specify).
Each of monitored side-effects (nausea, eructation, flatulence, diarrhoea) during and 2h after drinking was evaluated by either point 0 (no side-effects) or point 1 (side-effect present -without severity assessment).
Oral contrast agent solution
The tested experimental solution (1000 ml) was composed of: maghemite nanoparticles 800 mg, bentonite matrix 4 g, fruit juice 500 ml-apple/carrot (HAMI, Nutricia, CZ), water 500 ml, polyethylene glycol 4000 (Macrogol) 76.8 g + 2.82 g sodium sulphate (Na 2 SO 4 ) + 0.84 g sodium bicarbonate (NaHCO 3 ) + 0.72 g sodium chloride (NaCl) + 0.36 g potassium chloride (KCl). Fruit juice acts against the nanoparticle sedimentation in the bowel and is useful for homogenic lay out of solution in the bowel. Additionally, the taste of the experimental solution is further improved by the fruit juice.
Study assessment
To define the best signal intensity (SI) of the intraluminal lay out the maghemite concentrations 200, 400, 600, 800 and 1000 mg /4 g bentonite of the experimental solution were tested in healthy volunteers (group A). The final concentration of the experimental solution was compared to the commercially available solution ferumoxsil (Lumirem, Guerbet, France) in group A (Fig. 3,4,5,6 ). Four specialists in gastrointenstinal MRI evaluated all MR results in studied groups.
Groups A and C drank 1000 ml of experimental solution with maghemite fractionally within 50 min followed by MREg without intravenous contrast agent and spasmolytics. Group B drank 500 ml of experimental solution fractionally within 30 min followed by MRCP without intravenous contrast agent and spasmolytics.
Imaging protocol
All examinations were realised on the MR unit 1. localiser, axial/coronal planes 2D T2 SSFSE TE 500, TR6000, bandwith 31.25, matrix 384 x 320, FOV 36, coronal plane 3D FIESTA, MRCP-slice thickness 20 mm, spacing 0, number of slices 14 and more.
All image analyses were performed on the workstation ADW 4.5 (GE, Milwaukee,Wisconsin, USA).The matrix size and resolution of the monitors were 1500 x 2000 (3 megapixels).
Statistics
Pearson's chi-square test and Fisher's exact test were used for the evaluation of categorical variables. Quantitative parameters were analysed by KruskalWallis test and nonparametric Mann-Whitney test with Bonferroni correction was used for analysis of significant results. All tests were made at the level of significance P≤0.05. Data were analyzed by SPSS v.15 software (SPSS Inc., Chicago, USA).
RESULTS
Based on visual assessment of four MRI specialists the concentration of 800 mg maghemite/4 g bentonite in 1000 ml of the experimental solution was optimal for proper intramurally lay-out in all 3 groups. The concentration of 800 mg maghemite/4 g bentonite was comparable to ferumoxsil (Lumirem, Guerbet) for MREg in group A according to visual assessment (Fig. 5,6 ).
The amount of experimental solution 1000 ml vs 500 ml evaluated by patients and healthy volunteers according to scoring system was not statistically significant between groups (P=0.085). The taste of the solution did not differ significantly in groups A, B and C (P=0.097), however, 20% of the women across the groups described a bad taste of the solution. There was no significant difference in characteristic of the taste among groups A, B and C (P=0.298). The tested solution appearance was not found to be significant in all groups (P=0.319). The relationship between the taste, characteristic of the taste and appearance was statistically significant across the groups: fruity taste was associated with good taste and good-looking appearance (P=0.05); metallic taste was associated with bad taste and bad-looking appearance (P=0.05).
Side-effects during and 2h after drinking in all groups are summarized in (Table 2 ). The most common sideeffects during drinking of the experimental solution were nausea (29.4%) and eructation (29.4%) in group A and diarrhoea (27.3%) in group C.
Side-effects 2h after drinking the experimental solution occured in group A (nausea 17.6%) and in group C (diarrhoea 54.6%). Once the side effects occured during drinking, they persisted for up to 2h after drinking (P=0.05). None of the patients in group B suffered from problems 2h after drinking the experimental solution. Based on the evaluation of all side effects during and 2h after drinking the best tolerated experimental solution was in group B when compared to group A (P=0.0003) and to group C (P=0.002), respectively. Side-effects of the solution in groups A and C did not differ significantly. The Spearman correlation analysis showed a significant relationship between overall evaluation of experimental solution and age: the older subjects assessed the solution more favorably than the younger one ( r/y = -0.482). The best tolerance of the experimental solution was found in the group B with significantly higher median age of patients age than groups A and C.
DISCUSSION
Superparamagnetic iron oxide MR imaging contrast agents have been the subject of extensive research over the past decade 10 . Iron oxide particles for bowel contrast are coated with insoluble material, and all iron oxide particles for intravenous injection are biodegradable. Superparamagnetic agents open up an important field for research in MR imaging. Rieber et al. used positive and negative oral contrast agents in MREc for better delineation of interloop abscesses in Crohn's disease. T2-weighted sequences were necessary using negative oral contrast media, because loop abscesses may be masked. Magnetic resonance imaging should be performed in all patients with a suspicion of extraintestinal complications, because the complications are more reliably detected by MRI (Fig. 7) . Negative oral contrast media show advantages with the use of intravenous contrast but can mask loop abscesses using only T1-weighted imaging 13 . A new superparamagnetic iron oxide contrast agent ferristene is a safe and effective endoluminal contrast medium used for magnetic resonance (MR) enteroclysis 14 . This study evaluated the applicability of experimental oral contrast solution with maghemite for MRCP and MREg examinations in patients with small bowel diseases.
Based on visual assessment and the consensus of four MRI specialists, the concentration of 800 mg maghemite/4 g bentonite in 1000 ml of experimental solution was optimal for the proper intramurally lay-out required for MREg and MRCP (Fig. 8 ) in all 3 groups. In MREg this concentration of experimental solution was comparable with the commercial solution ferumoxsil (Lumirem,Guerbet). Both solutions are negative contrast agents based on superparamagnetic iron oxide complexes. T2-weighted MR with superparamagnetic oral contrast agent ferumoxsil is used in Crohn's disease and helps to assess mural and transmural inflammation with the same accuracy as gadolinium-enhanced T1-weighted MR (Fig. 7) . The combination of gadolinium-enhanced T1-and T2-weighted sequences is useful in the assessment of Crohn's disease 2 . In our experience the solution with maghemite is suitable for MREg examination for all tested indications: non-specific enteritis, Crohn's disease, celiac disease, chronic small bowel inflammation, changes of small bowel in liver diseases, acute and chronic pancreatitis.
The experimental solution of 500 ml was used for MRCP examination to suppress the signal intensity in the proximal loops of the small bowel and for better depiction of the biliary tree especially in liver cirrhosis and free intra-abdominal fluid (Fig. 8) . The MRI specialists generally recommend 1000 ml of the experimental solution to depicting of the whole small bowel. There were no significant differences in the evaluation of experimental solution quantity(1000 ml vs 500 ml) based on questionnaires from patients and healthy volunteers.
Fruit juice was added to the experimental oral contrast solution to improve its taste. The difference in taste was not peceived over groups, but the taste perception was gender specific: 20% of women across the groups described a bad solution taste. The characteristic of taste and appearance of experimental solution did not differ significantly among groups. We analysed the relationship among the taste, characteristic of the taste and appearance and we found a significant correlation of fruity taste with good taste and good-looking appearance. In contrast, metallic taste was associated with bad taste and bad-looking appearance. Most of the side-effects (nausea, eructation and diarrhoea) occured during drinking of the experimental solution in groups A and C. Once the sideeffects occured during drinking, they persisted up to 2h after drinking in both groups A and C. Group B tolerated experimental solution with minimum of side-effects. Better evalution of the solution in the group B was influenced by the older age of these patients than groups A and C. Interestingly, volunteers and patients in groups A and B aged over 50 years did not complain of problems during and after drinking. This could be partly explained by the fact that in general the older population covers up information about their health problems. Side effects of the experimental solution did not differ between the healthy volunteers (group A) and patients with small bowel diseases (groups B,C). On T1-weighted images simultaneous use of negative oral contrast agents and intravenous injection of gadolinium-chelate produces the best conditions for double-contrast techniques. The combination of negative oral contrast agents and intravenous injections of gadolinium chelate increases significantly the contrast between the wall and pathological findings in the wall (inflammatory changes and tumors) (ref. 7 ).
CONCLUSION
The experimental maghemite solution including quantity, taste and appearance was well-tolerated in all studied groups. Our study supports the use of this solution in MRI practice. More studies are needed to confirm our results in adult and pediatric patients with small bowel diseases.
